AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Description: Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.
Study NCT04982913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Study NCT06289517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Her2-affibody
Description: 68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Study NCT06738043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Description: A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.
Study NCT05238740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ViviGen®
Description: It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
Study NCT05238740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rhBMP-2
Description: It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
Study NCT05533411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV.
Study NCT05533411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study NCT06585696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CU-20101 treatment for Moderate to Severe Glabellar Striae
Description: Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36).
Study NCT06585696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20101 treatment for Moderate to Severe Glabellar Striae
Description: Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36).
Study NCT05683132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed CBT-I
Description: 5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.
Study NCT05683132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Psychoeducation
Description: 5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
Study NCT06380179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THOR3 training + Photobiomodulation Therapy (PBMT)
Description: PBMT will be delivered at 32-40W (depending on participant skin pigmentation). PBMT will be applied to the quadriceps area. A study team member will use the quadriceps measurements of the treatment area to calculate the PBMT treatment time (approximately 5-20 minutes) and specified J/cm2. PBMT treatment will be provided 3 times per week, for 3 weeks.~PBMT will be delivered by a trained study team member using the LightForce® XLi 40W device with the Smart Hand Piece technology, which has a built-in accelerometer in the hand piece that controls the speed of light delivery to the treatment area. The trained team members will use the Smart Hand Piece technology, which assesses the operator's speed and provides real-time visual and sensory feedback calibrated to shut-off when moving too slowly and warns the operator when moving too quickly by vibrating. Treatment is delivered through a flexible optical fiber threaded through the hand piece, which contains a rolling glass massage ball.
Study NCT06738043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Infusion (Placebo)
Description: A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
Study NCT06380179 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: THOR3 training + sham PBMT
Description: Sham PBMT will be provided by a trained study team member. Sham PBMT will be delivered in the same manner as indicated for the PBMT process above, but the device will stay in standby mode (i.e., the treatment mode will not be turned on). As infrared light is invisible to the naked eye, the only visible difference between treatment and standby modes is the presence of a few tiny amber lights (these lights are on during treatment mode).
Study NCT06655675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the umbilical artery
Study NCT06738888 — intervention group
Intervention type: OTHER
Intervention: Observations on clinicopathological factors influencing the difficulty of surgery
Description: Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data, thyromental distance, neck circumference, sternomental distance, ratio of height-to-thyromental distance, RHTMD, ratio of height-to-sternomental distance, RHSMD
Study NCT05668858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Administration by intravenous infusion
Study NCT05668858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion
Study NCT06740422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuanhuang Runtong Tablet
Description: A synthetic tablet is mainly composed of Radix Rehmanniae, Radix Scrophulariae, Radix Angelicae Sinensis, Semen Persicae, Herba Cistanches, Fructus Cannabis, Semen Cassiae, Fructus Aurantii Immaturus and Aloe.
Study NCT06740422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xuanhuang Runtong Tablet Simulator
Description: Xuanhuang Runtong Tablet Simulator
Study NCT06168851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD38 antibody Injection
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Study NCT06387199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide with 4 meal strategies
Description: The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
Study NCT06387199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo with 4 meal strategies
Description: The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
Study NCT05290597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI363
Description: a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
Study NCT05921630 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Patient education before pulmonary function test
Study NCT04978753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;
Study NCT05460780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MATTISSE TEC
Description: Tissue engineering chamber MATTISSE
Study NCT05486156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A Time with e-Nature
Description: Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group.
Study NCT05486156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Time with e-Nature
Description: Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group.
Study NCT06532565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-2121
Description: Tablet administered orally
Study NCT06532565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously
Study NCT05201339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard method
Description: Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
Study NCT05201339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hean and Neck Rotation
Description: After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
Study NCT05574270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IC-8 Intraocular Lens (IOL)
Description: A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
Study NCT05885412 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RP-A601
Description: RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)
Study NCT06541145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Participants will place a pea-sized amount (or approximately 1cm ribbon) of 2% mupirocin ointment (Duke formulary) on a cotton swab and gently massage it into the anterior nares twice daily for 5 days.
Study NCT06541145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine baths
Description: Participants will be instructed to use pre-packaged chlorhexidine cloths. Each cloth will be used to wipe designated body areas (i.e., arms, legs, chest and neck, back and perineum) once a day for 5 days. These are inexpensive cloths that are easy to use and have been shown to be effective at eradicating Staph aureus carriage. Ideally, participants will be instructed not to rinse off immediately after using the cloths. Baths should be performed on the same 5 days as they apply the intranasal mupirocin.
Study NCT05183126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.
Study NCT05183126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time.
Study NCT05387954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure
Description: PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.
Study NCT05387954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Anticoagulant, Direct-Acting
Description: Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
Study NCT05387954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet therapy
Description: Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
Study NCT05387954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Description: Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
Study NCT04823169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: podobarometry
Description: podobarometric measures on day 7 and day 30
Study NCT06541327 — intervention group
Intervention type: DRUG
Intervention: Chimeric Antigen Receptor
Description: CAR-T
Study NCT04931810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All Nations Breath of Life
Description: Same.
Study NCT05795504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistive exercise
Description: They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.
Study NCT05795504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity interval training
Description: They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,
Study NCT05795504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium and vitamin D
Description: they will receive calcium and vitamin D supplements only.
Study NCT05795504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium and vitamin D
Description: they will receive calcium and vitamin D supplements only.
Study NCT06082102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib Tablets
Study NCT06082102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide Capsules
Study NCT06082102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide Capsules
Study NCT06082102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab Injection
Study NCT06082102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab Injection
Study NCT06082102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orelabrutinib Placebo
Description: Orelabrutinib Placebo Tablets
Study NCT06562231 — intervention group
Intervention type: OTHER
Intervention: quality of life scale
Description: This study will be conducted on women diagnosed with symptomatic isthmocele after cesarean section. Researchers will prepare scale questions, and the survey questions will be developed after obtaining an expert opinion from 20 experts to be evaluated by psychiatry, obstetrics, and public health experts. The patient will fill out the questionnaire form with the diagnosis of isthmocele. Oral and written consent will be obtained from the patients.
Study NCT05608642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous hydration
Description: 500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
Study NCT05608642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous prednisolone
Description: The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
Study NCT05608642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine
Description: The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
Study NCT06604624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD1916
Description: HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
Study NCT06604624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
Study NCT06593522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Film-coated tablet
Study NCT06575036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The starting dose of sugammadex will be 0.5mg/kg. When the dose for a patient was not effective, the dose for next patient will be increased by 0.5mg/kg. When the dose was effective, the dose for next patient will be decreased by 0.5mg/kg or maintained, with a 1:1 of allocation ratio.
Study NCT05921630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patient education before pulmonary function test
Study NCT05456815 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized diet
Description: During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
Study NCT04754984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor workshop
Description: Physiotherapist-led workshop on managing pelvic floor symptoms
Study NCT05231603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: 0.4 mg/kg/day-maximum dose is 24 mg.
Study NCT05231603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar to drug in term of tablets
Study NCT05411276 — intervention group
Intervention type: DRUG
Intervention: Pyrotinib maleate
Description: Pyrotinib maleate tablets 400 mg/day, oral within 30 minutes after breakfast, every 4 weeks is a cycle
Study NCT05928247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training (FCT)
Description: During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), the investigators also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), the investigators will recommend using a chained schedule FCT (chained-FCT).
Study NCT05928247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Contingent Reinforcement (NCR)
Description: During NCR, the investigators will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).